Hepatocellular carcinoma is the most common primary malignancy
of the liver, with increasing incidence worldwide. Chronic
liver diseases, especially liver cirrhosis, are the primary
risk factors in the pathogenesis. Curative therapy is usually
possible only in early disease, however, most cases are
diagnosed at advanced stage. Until recently sorafenib was the
only viable option for systemic treatment, however, over the
past years many new targeted and immunotherapy drugs proved to
be efficient in first and second line as well
